ALTA 2618
Alternative Names: ALTA-2618Latest Information Update: 06 Sep 2024
At a glance
- Originator Alterome Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Breast cancer; Endometrial cancer
Most Recent Events
- 22 Aug 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO)
- 01 Aug 2024 Alterome Therapeutics plans a phase I trial for Solid tumour (Metastatic disease, Inoperable/unresectable, Second-line therapy or greater, Late-stage disease) in the US (PO) (NCT06533059)
- 12 Apr 2024 Alterome Therapeutics has patent protection for ALTA 2618 in World